Arcturus Therapeutics Holdings Inc. — Form 8-K Summary
Business Context and Reporting Period
Current report dated August 2, 2019, concerning a registered direct offering of common stock. The filing does not report quarterly or annual operating results. The report was signed on August 5, 2019.
Transaction and Key Financial Metrics
- On August 2, 2019, the company entered into a securities purchase agreement with an additional institutional investor for 200,000 shares at $11.50 per share.
- Gross proceeds from this additional offering are $2.3 million.
- Estimated net proceeds are approximately $2.1 million after placement-agent fees and estimated offering expenses.
- Separately, securities purchase agreements entered into on August 1, 2019 covered 945,653 shares at $11.50 per share, generating gross proceeds of $10.875 million and estimated net proceeds of $10.1 million.
- Combined disclosed offering shares total 1,145,653, with aggregate gross proceeds of approximately $13.175 million and estimated combined net proceeds of approximately $12.2 million.
- The placement agent is entitled to a cash fee equal to 6.0% of gross proceeds plus $75,000 of expenses.
- The filing provides no operating revenue, profit, cash-flow, margin, debt, or liquidity balances.
Material Changes Versus the Prior Comparable Period
No prior comparable operating period is presented. The material change disclosed is the planned issuance of additional equity and the expected increase in cash from the offering.
Guidance, Outlook, Risks, and Unusual Items
- The offering was expected to close on or about August 5, 2019, subject to customary closing conditions; the filing does not confirm closing in the provided text.
- The shares are registered under the company’s effective Form S-3 registration statement No. 333-232281.
- The transaction is subject to the terms, representations, warranties, and covenants in the securities purchase agreement. The filing cautions that these provisions allocate risk and should not be treated as factual statements about the company.
- The offering will dilute existing stockholders through the issuance of 1,145,653 shares, assuming both disclosed transactions close.
- The filing includes a legal opinion regarding the validity of the share issuance and a press release furnished under Regulation FD.
Investor Verification Checklist
- Verify whether the offering closed and whether all 1,145,653 shares were issued.
- Confirm actual net proceeds and offering expenses against the estimated amounts.
- Review the securities purchase agreement, placement-agent engagement letter, and related registration statement.
- Assess the resulting share-count dilution and the company’s subsequent use of proceeds.
- Review later filings for updates to cash, liquidity, financing needs, and any contingencies related to the offering.